drugset / Trial / NCT03314935

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

NCT03314935

Phase 1/2 Completed 149 enrolled Incyte Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.

Timeline

Start
2017-11-21
Primary completion
2022-11-28
Completion
2022-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified
Subject Gemcitabine Small molecule
Subject Leucovorin Small molecule
Subject NUMIDARGISTAT Small molecule Oral
Subject Oxaliplatin Small molecule Intravenous
Subject Paclitaxel Small molecule
Subject fluorouracil Small molecule